nystatin-a1 and Trichomonas-Vaginitis

Topics: Antifungal Agents; Bacterial Infections; Candidiasis, Vulvovaginal; Clotrimazole; Drug Administration Schedule; Female; Humans; Metronidazole; Miconazole; Nystatin; Trichomonas Vaginitis; Vaginitis

Infectious vaginitis occurs when the normal vaginal flora is disrupted; it may arise when saprophytes overwhelm the host immune response, when pathogenic organisms are introduced into the vagina or when changes in substrate allow an imbalance of microorganisms to develop. Examples of these types of vaginitis include the presence of chronic fungal infection in women with an inadequate cellular immune response to the yeast, the introduction of trichomonads into vaginal epithelium that has a sufficient supply of glycogen, and the alteration in bacterial flora, normally dominated by Lactobacillus spp., and its metabolites that is characteristic of "nonspecific vaginitis". The authors review microbiologic and clinical aspects of the fungal, protozoal and bacterial infections, including the interactions of bacteria thought to produce nonspecific vaginitis, that are now recognized as causing vaginitis. Other causes of vaginitis are also discussed.

Topics: Antibody Formation; Antifungal Agents; Candidiasis; Candidiasis, Vulvovaginal; Carrier State; Female; Gardnerella vaginalis; Haemophilus Infections; Humans; Lactobacillus; Male; Metronidazole; Mycoplasma Infections; Nystatin; Pregnancy; Pregnancy Complications, Infectious; Sexual Behavior; Streptococcal Infections; Streptococcus agalactiae; Trichomonas Vaginitis; Vagina; Vaginitis; Virus Diseases

Topics: Adult; Candidiasis; Clinical Laboratory Techniques; Diagnosis, Differential; Female; Haemophilus Infections; Humans; Metronidazole; Nystatin; Recurrence; Sulfonamides; Trichomonas Vaginitis; Vaginal Diseases; Vaginitis; Vulvovaginitis

The evaluation of combined and miscellaneous vulvovaginal infections incidence and their treatment with combined vaginal products containing nifuratel and nystatin.. Prospective study.. Gynecologic outpatient department LEVRET, Prague; Laboratories of Microbiology AescuLab, Prague.. 70 consecutive patients were examined with complaint of vaginal fluor and/or pruritus. We established macroscopic features of fluor, pH, amine test and mounts stained with Giemsa and Gram. We qualified the cases with more diagnostic criteria (mycosis, lactobacillosis, anaerobic vaginosis, aerobic vaginitis) as combined infection, those with no diagnostic criteria as miscellaneous. We treated all patients with vaginal tablets nystatin + nifuratel (Macmiror complex). We prescribed clotrimazol cream, if pruritus was present. We evaluated withdrawals of symptoms and relapses during 3 months after treatment.. Combined infection was found in 21 patients from 70 (30%). The most frequent combination was that of mycosis and aerobic vaginitis (13/70, 18.6%) or mycosis and anaerobic vaginosis (4/70, 5.7%); 11 patients fulfilled criteria of no diagnosis. We concluded them as "miscelaneous". The treatment was successful in all cases, 10 women relapsed in 3 months.. Combined vaginal infection findings are present very often (30%), likewise miscellaneous ones (15%) occur. The treatment of these women in successful with vaginal tablets with nystatin + nifuratel.

Topics: Administration, Intravaginal; Adult; Anti-Bacterial Agents; Antifungal Agents; Antitrichomonal Agents; Candidiasis, Vulvovaginal; Clotrimazole; Drug Combinations; Female; Humans; Middle Aged; Nifuratel; Nystatin; Trichomonas Vaginitis; Vaginosis, Bacterial; Vulvovaginitis

The dose-effect relationship of nifuratel (CAS 4936-47-4) + nystatin (CAS 1400-61-9, CAS 34786-70-4) (Macmiror Complex) in topical treatment of vulvo-vaginitis was studied.. Sixty patients with Trichomoniasis and/or Candidiasis were randomized to: 1) nifuratel 125 mg/nystatin 50000 IU, 2) nifuratel 250 mg/nystatin 100000 IU, 3) nifuratel 500 mg/nystatin 200000 IU. Undistinguishable ovules were intravaginally applied qd for 10 days. The dose-effect relationship was assessed by ANCOVA.. After 5 days the microbiological cure rate occurred in 10% of patients in the least dose, in 40% in the middle dose and in 85% in the highest dose group (P = 0.000). After 10 days of treatment, the microbiological cure rate increased to 45%, 84%, and 95%, respectively (P = 0.007). Clinical signs and symptoms gradually disappeared in a dose- and time-dependent manner. No relapse has been observed after 10 day-follow up on 46 patients.. The results confirmed a linear relationship between nifuratel + nystatin dose and effect. The least effective dose was nifuratel 250 mg + nystatin 100,000 IU once daily for 5 days and the best dose in terms of risk/benefit ratio was nifuratel 500 mg + nystatin 200,000 IU once daily for 5 days.

Topics: Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Middle Aged; Mycoses; Nifuratel; Nystatin; Treatment Outcome; Trichomonas Vaginitis; Vaginal Diseases

To assess the effect of treatment of vaginal infections on vaginal shedding of cell-free human immunodeficiency virus type 1 (HIV-1) and HIV-1-infected cells, HIV-1-seropositive women were examined before and after treatment of Candida vulvovaginitis, Trichomonas vaginitis, and bacterial vaginosis. For Candida (n=98), vaginal HIV-1 RNA decreased from 3.36 to 2.86 log(10) copies/swab (P<.001), as did the prevalence of HIV-1 DNA (36% to 17%; odds ratio [OR], 2.8; 95% confidence interval [CI], 1.3-6.5). For Trichomonas vaginitis (n=55), HIV-1 RNA decreased from 3.67 to 3.05 log(10) copies/swab (P<.001), but the prevalence of HIV-1 DNA remained unchanged (22%-25%; OR, 0.8; 95% CI, 0.3-2.2). For bacterial vaginosis (n=73), neither the shedding of HIV-1 RNA (from 3.11 to 2.90 log(10) copies/swab; P=.14) nor the prevalence of DNA (from 21% to 23%; OR, 0.8; 95% CI, 0.3-2.0) changed. Vaginal HIV-1 decreased 3.2- and 4.2-fold after treating Candida and Trichomonas, respectively. These data suggest that HIV-1 transmission intervention strategies that incorporate diagnosis and treatment of these prevalent infections warrant evaluation.

Topics: Adult; Anti-Bacterial Agents; Antitrichomonal Agents; Candidiasis; DNA, Viral; Down-Regulation; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Metronidazole; Nystatin; Odds Ratio; Prospective Studies; RNA, Viral; Trichomonas Vaginitis; Vagina; Vaginitis; Vaginosis, Bacterial; Virus Shedding

The aim of the present multicentre study was to examine the therapeutic possibilities of the wide-spectrum medicament MACMIROR & MACMIROR COMPLEX for the treatment of the vaginal infections.. The study included 159 nonpregnant women among 15 and 54 years (middle age 35.6) with different by kind and intensity colpitis complaints. The following microbiological characteristic was established: in 26 cases Gardnerella vaginalis, in 46 Candida spp., and in the rest 87-mixed aerobic bacterial flora, with a combination of Gardnerella, yeast and Trichomonas. The treatment of the patients was done in combined scheme: peroral and vaginal administration, simultaneously with local treatment of the partner. The control examination was performed bistagely: on 7-10 day and on 30-40 day.. The good clinical and microbiological influence of the treated patients was established, for the first control examination the effect was found in 88.1% and 86.8% and for the second--respectively in 81.1% and 82.4%.. The received results give us a cause to approve, that the combination "Nifuratel and Nystatin" (Macmiror & Macmimor complex) has the good possibilities to influence the mixed forms of vaginal infection.

Topics: Adolescent; Adult; Anti-Bacterial Agents; Antifungal Agents; Antitrichomonal Agents; Candidiasis, Vulvovaginal; Drug Combinations; Female; Gardnerella vaginalis; Humans; Middle Aged; Nifuratel; Nystatin; Treatment Outcome; Trichomonas Vaginitis; Vaginosis, Bacterial

(1) To compare the effectiveness of two clinical protocols for the management of vaginal discharge in the situations where no laboratory facilities are available but speculum examination is possible and where basic laboratory facilities are available. (2) To determine clinical and simple laboratory indicators for diagnosis of patients with vaginal discharge in the local setting.. Alternate allocation of subjects to one of two management protocols.. Women presenting to university gynaecology outpatients department with a complaint of vaginal discharge.. Subjects were alternately allocated management according to one of two protocols: one without (group A) and one with (group B) immediate access to results of basic laboratory tests. Full clinical assessment including speculum examination and microbiological assessment for infection with gonorrhoea, chlamydia, candida, trichomonas, and bacterial vaginosis was performed on all women. Follow up assessment of clinical and microbiological response was performed 1-2 weeks later.. At initial assessment, both groups were similar in all respects except that more group B women had inflammation of the vulva. The prevalences of various conditions were: candidiasis 22%, bacterial vaginosis 38%, trichomoniasis 4%, chlamydia 4%, gonorrhoea 0.4%. There was no association between any demographic characteristic and diagnosis of cause of the discharge. Both protocols resulted in clinically and statistically significant improvements for women with candidiasis, bacterial vaginosis, and trichomoniasis. There were no clinically important differences in outcomes between the two protocols. The sensitivities and specificities of various indicators were: curd-like vaginal discharge for candidiasis, 72% and 100%; homogeneous vaginal discharge for bacterial vaginosis or trichomoniasis, 94% and 88%; absent or scanty lactobacilli for bacterial vaginosis, 99% and 68%; > 20% clue cells for bacterial vaginosis, 81% and 99%; visible endocervical mucopus for chlamydia or gonorrhoea, 36% and 86%; microscopic endocervical mucopus for chlamydia or gonorrhoea, 64% and 69%.. Both protocols were equally effective in managing women with abnormal vaginal discharge. Simple clinical indicators for candidiasis, bacterial vaginosis, or trichomonas as in protocol A are sufficiently sensitive and specific for use in situations with no laboratory support. A modification to protocol A could increase detection of bacterial vaginosis at basic health service level. Further work is needed to identify appropriate indicators for infection with chlamydia or gonorrhoea.

Topics: Adult; Anti-Infective Agents; Candidiasis, Vulvovaginal; Clinical Protocols; Doxycycline; Female; Gonorrhea; Humans; Leukorrhea; Metronidazole; Microbiological Techniques; Middle Aged; Nystatin; Ofloxacin; Physical Examination; Trichomonas Vaginitis; Uterine Cervicitis; Vaginosis, Bacterial

Topics: Candidiasis, Vulvovaginal; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Metronidazole; Nifuratel; Nitrofurans; Nystatin; Trichomonas Vaginitis; Vaginitis

Topics: Adult; Candida albicans; Candidiasis, Vulvovaginal; Clinical Trials as Topic; Drug Combinations; Evaluation Studies as Topic; Female; Humans; Metronidazole; Muramidase; Nystatin; Suppositories; Trichomonas vaginalis; Trichomonas Vaginitis

Topics: Adult; Aged; Antifungal Agents; Candidiasis, Vulvovaginal; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Humans; Metronidazole; Middle Aged; Nystatin; Polyamines; Trichomonas Vaginitis

Topics: Antifungal Agents; Clinical Trials as Topic; Female; Humans; Hydrogen-Ion Concentration; Metronidazole; Mycoses; Natamycin; Nystatin; Trichomonas Vaginitis; Vaginitis

The group of experts representing the Polish Gynecologic Society has issued this statement based on the review of available literature on the potential benefits of the use of Macmiror Complex 500 in obstetrical and gynecologic practice. Mixed Vaginitis (MV) eg. the vaginal infection caused by at least two out of the triad of pathogens (fungi, bacteria and Trichomonas Vaginalis [TV]), constitutes the type of vaginitis which is underestimated as for its prevalence. Mixed pathogens are responsible for as much as one third of all vaginal infections. Macmiror Complex 500 contains two active ingredients: nifuratel and nystatin. Macmiror Complex 500 affects all common causes of vulvovaginitis, i.e. bacteria, yeasts and TV. At the same time, it is not effective against Lactobacillus spp., which is a clear advantage in the treatment of vaginal infections. The antibacterial spectrum of nifuratel includes aerobic and anaerobic bacteria. Moreover nifuratel is effective against Chlamydia trachomatis and Mycoplasma spp., it has an anti-trichomonal effect comparable to metranidazole and shows certain activity against Candida spp. Nystatin is effective against Candida albicans and is even very effective against Candida glabrata which is usually more resistant to imidazole antifungal agents. Nystatin's importance is rising due to the current increase of candidoses caused by non-albicans types. This increase is especially perceptible in recurring candidoses. The review of the available literature on the effectiveness of Macmiror Complex 500 in the OB/GYN practice leads to the following conclusions: the exeptionally broad antibacterial and antifungal and trichomonicidal activity of this formulation makes it a drug of choice in cases where MV is suspected. The possibility to treat both partners, favorable safety profile in pregnant patients and the availability of both vaginal ovules and the cream with applicator makes this drug an effective and suitable treatment option in obstetrical and gynecologic practice.

Topics: Antifungal Agents; Antitrichomonal Agents; Drug Combinations; Female; Gynecology; Humans; National Health Programs; Nifuratel; Nystatin; Obstetrics; Poland; Pregnancy; Quality Assurance, Health Care; Societies, Medical; Trichomonas Vaginitis; Vulvovaginitis; Women's Health

The aim of the present study was to examine the therapeutic possibilities of the wide-spectrum medicament Macmiror & Macmiror Complex for the treatment of the vaginal infections.. The study included 52 nonpregnant women among 20 u 54 years (middle age 30.5) with different by kind and intensity colpitis complains. The following microbiological characteristic was established: in 26 cases Candida spp., in 19 Gardnerella vaginalis, in 1 Trichomonas vaginalis and in the rest 6 mixed infection. The treatment of the patients was done in combined scheme: peroral and vaginal administration simultaneously with local treatment of the partner. The control examination was performed bistagely: on 7-10 day and on 30-40 day.. The good clinical and microbiological influence of the treated patients was established for the first control examination the effect was found in 89.5% u 84.2% go of the cases with bacterial vaginosis and in 84.6% u 69.2% in those with mycotic colpitis. Relatively high values were found also at the second control, respectively 83.3% and 72.2% for the amine colpitis and 69.5% and 52.2% for vaginal candidosis. The similar favorable influence received also in the rest of the patients.. Our results do show good possibilities of the nifuratel and nystatin combination (Macmiror & Macmiror complex) to influence vaginitis with different etiology, which give us founding to consider, that the drug is suitable for the mixed forms of vaginal infection.

Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Antitrichomonal Agents; Candidiasis, Vulvovaginal; Drug Combinations; Drug Evaluation; Female; Gardnerella vaginalis; Humans; Middle Aged; Nifuratel; Nystatin; Trichomonas Vaginitis; Vaginosis, Bacterial

Vaginitis is one of the most common complaints of women in the United States today. About 90% of patients with this problem suffer from infection of the vagina caused by Candida, Gardnerella, or Trichomonas. The diagnosis and effective treatment of these common infections depend on accurate identification of the entity, effective specific therapy, and restoration of the normal ecosystem of the vagina. At the same time women should be made aware that not all discharge means infection and that any attempts at self-treatment may only worsen their condition. Proper hygiene habits, dietary control, and management of stress are all helpful factors in the control of recurrent vaginal infections.

Topics: Anti-Bacterial Agents; Candidiasis, Vulvovaginal; Female; Gardnerella vaginalis; Haemophilus Infections; Humans; Lactams; Male; Metronidazole; Nystatin; Recurrence; Sexual Behavior; Trichomonas Vaginitis; Vaginal Smears; Vaginitis

Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Candidiasis, Vulvovaginal; Female; Humans; Nifuratel; Nystatin; Trichomonas Vaginitis; Uterine Cervicitis; Vaginitis

Topics: Adult; Candidiasis, Vulvovaginal; Drug Combinations; Female; Humans; Middle Aged; Nifuratel; Nitrofurans; Nystatin; Trichomonas Vaginitis; Uterine Cervicitis; Vaginitis

Topics: Bacterial Infections; Candidiasis, Vulvovaginal; Female; Humans; Metronidazole; Miconazole; Nystatin; Recurrence; Trichomonas Vaginitis; Vaginitis

The current approach to the management of trichomoniasis and candidosis in sexually transmitted disease (STD) clinics in England and Wales is described. Microscopy alone was used in the diagnosis of trichomoniasis in 44% of clinics and of candidosis in 35% of clinics. Oral metronidazole was used for the treatment of trichomoniasis in women in 92% of clinics. Vaginal pessaries containing nystatin or clotrimazole were routinely used to treat candidosis in 95% of clinics. Male sexual contacts of female patients with candidosis and trichomoniasis were invited to attend for examination in 88% of clinics. Physicians in 81% of clinics prescribed treatment on epidemiological grounds for male contacts of female patients with trichomoniasis. A more uniform approach to the diagnostic categories used for the quarterly returns for cases treated epidemiologically is recommended.

Topics: Candidiasis, Vulvovaginal; Clotrimazole; Female; Humans; Male; Medical Records; Metronidazole; Nystatin; Trichomonas Vaginitis

Therapeutic failure in vaginitis can be minimized if all cases are properly diagnosed and specific therapy is given. Use of wet mounts combined with liberal use of cultures, especially for Corynebacterium vaginale, should result in an accurate diagnosis in over 90% of cases. Treatment of choice for candidiasis is nystatin or miconazole nitrate applied topically. For trichomoniasis, metronidazole should be given orally to both sexual partners. Ampicillin, cephalexin, or cephradine are recommended for C vaginale infection.

Topics: Ampicillin; Candidiasis, Vulvovaginal; Contraception; Corynebacterium Infections; Female; Humans; Metronidazole; Miconazole; Mycoses; Nystatin; Sexual Behavior; Trichomonas Vaginitis; Vaginitis

A positive microbiological evidence could be obtained 54 times from the smear of the exterior genitals of 80 women suffering from complaints that were caused by urethritis, criteria of the examinations being sterile catheter specimen, negative cystoscopical findings, and missing indications to anatomical changes in the urethral region. Cytological examinations of these cases with regard to the vaginal epithelium had the following results:Group I:6 times; group II: 37 times; group IIW:8 times; group IIId: once; group IVa:twice. The cytological tests were carried out according to the method of papanicolaou as modified by Soost. Furthermore, we could state the following degrees of purity: Degree I: 8 times; degree II:16 times; degree III: 30 times. The cytological examinations of the urethral epithelium demonstrated, in 52 cases, an increased appearance of "nude" completely exposed epithelial cell nuclei--a fact corresponding to a degenerative autolysis (according to Wied). In the 26 women with missing atypical germ flora within the region of the exterior genitals, exclusively groups I (according to Papanicolaou and Soost) and degrees of purity I were stated. These persons also demonstrated remarkably grave psychical disturbances, especially in the intimate regions. In the cases of positive microbiological evidence, the following measures have proved satisfactory: Vaginal hygienization combined with a directly aimed antibacterial therapy, and the prescription of preparations containing lactic acid. A transitory discontinuation of contraceptives is being discussed. Our examination results are emphasizing the necessity of an analysis of the germ flora in cases of complaints arising from urethritis. Also psychical disturbances must be taken into consideration in cases of missing urological and gynaecological criteria of evidence.

Topics: Candidiasis, Vulvovaginal; Cervix Uteri; Chronic Disease; Female; Humans; Male; Metronidazole; Mycoplasma Infections; Nystatin; Psychophysiologic Disorders; Tetracycline; Trichomonas Vaginitis; Urethra; Urethritis; Vagina; Vaginal Diseases

Topics: Adolescent; Adult; Antitrichomonal Agents; Candidiasis, Vulvovaginal; Female; Humans; Middle Aged; Nystatin; Thiazoles; Trichomonas Vaginitis

Topics: Adult; Antitrichomonal Agents; Arsenicals; Candidiasis; Drug Combinations; Female; Humans; Middle Aged; Neomycin; Nystatin; Polymyxins; Silicones; Trichomonas Vaginitis; Vulvovaginitis

Topics: Adolescent; Candida albicans; Candidiasis, Vulvovaginal; Child; Corynebacterium Infections; Female; Gonorrhea; Haemophilus Infections; Herpes Simplex; Humans; Hydrogen-Ion Concentration; Metronidazole; Mycoplasma Infections; Nystatin; Pregnancy; Pregnancy Complications, Infectious; Trichomonas Vaginitis; Tuberculosis, Urogenital; Vagina; Vaginitis

Topics: Administration, Oral; Administration, Topical; Amphotericin B; Animals; Antifungal Agents; Candida; Candida albicans; Candidiasis; Cricetinae; Drug Evaluation, Preclinical; Female; Guinea Pigs; Hexachlorophene; Mice; Natamycin; Nystatin; Rats; Tetracycline; Trichomonas Infections; Trichomonas vaginalis; Trichomonas Vaginitis; Vaginitis

Topics: Administration, Oral; Adult; Candida albicans; Drug Combinations; Female; Humans; Imidazoles; Morpholines; Nitro Compounds; Nystatin; Pessaries; Pregnancy; Tetracycline; Trichomonas Vaginitis

Topics: Adolescent; Adult; Candidiasis, Vulvovaginal; Drug Combinations; Female; Humans; Middle Aged; Nitrofurans; Nystatin; Trichomonas Vaginitis

A guest faculty discussed the management of patients with vaginal infections. It was agreed that correct diagnosis is necessary before therapy. Diagnosis can be accomplished by a microscopic examination in 90% of the cases. The cytologic smear is also very important. Specific culture media may be useful for troublesome cases, for instance, blood agar fo Haemophilus vaginalis, Trichocel medium for Trichiomonas vaginalis, Neckerson's medium for candidal species and Thayer-Martin for Neisseria gonorrhoeae. Patient history is important since some infections tend to occur in certain patients such as candidiasis in patients with diabetes mellitus, patients who are pregnant or are taking broad spectrum antibiotics, estrogen or contraceptive pills. The pH of vaginal secretions may also be helpful in making the diagnosis. It was suggested that the term "nonspecific" vaginitis is a misnomer and is used to conceal ignorance. Others felt that such agents as soap, vaginal deodorant spray, and clothing may be causatives. The term "psychogenic leukorrhea" was discussed with varying conclusions. Routine treatment for each form of vaginitis was outlines and treatment for recurrent, persistent trichomoniasis and moniliasis was given. It was agreed that douching will not cure vaginitis but may be useful in removing excessive secretion. It is not recommended for routine hygeine but is acceptable following menstruation or intercourse.

Topics: Adult; Candidiasis, Vulvovaginal; Child; Chronic Disease; Clioquinol; Estrogens, Conjugated (USP); Female; Haemophilus Infections; Humans; Leukorrhea; Metronidazole; Nitrofurazone; Nystatin; Pregnancy; Sulfates; Therapeutic Irrigation; Trichomonas Vaginitis; Vagina; Vaginal Smears; Vaginitis

Topics: Adult; Aged; Candidiasis, Vulvovaginal; Female; Humans; Metronidazole; Middle Aged; Natamycin; Nystatin; Pregnancy; Trichomonas Vaginitis

Topics: Adolescent; Adult; Candidiasis, Vulvovaginal; Drug Resistance, Microbial; Female; Gonorrhea; Humans; Intrauterine Devices; Metronidazole; Neisseria gonorrhoeae; Nigeria; Nystatin; Penicillin Resistance; Sexually Transmitted Diseases; Tetracycline; Trichomonas Vaginitis

Topics: Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Drug Combinations; Female; Humans; Middle Aged; Nystatin; Oxytetracycline; Trichomonas Vaginitis

Topics: Adult; Alcohols; Behcet Syndrome; Candidiasis, Vulvovaginal; Colposcopy; Condylomata Acuminata; Cryosurgery; Female; Fluorouracil; Genital Diseases, Female; Herpes Labialis; Humans; Lichen Planus; Menstruation Disturbances; Neurodermatitis; Nystatin; Podophyllin; Progestins; Testosterone; Triamcinolone Acetonide; Trichomonas Vaginitis; Vaginal Smears; Vulvovaginitis

Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Candidiasis, Vulvovaginal; Estrogens; Female; Humans; Leukorrhea; Metronidazole; Nystatin; Pregnancy; Trichomonas Vaginitis

Topics: Evaluation Studies as Topic; Female; Humans; Metronidazole; Nystatin; Trichomonas Vaginitis

Topics: Administration, Oral; Adult; Candidiasis, Vulvovaginal; Drug Tolerance; Female; Humans; Metronidazole; Middle Aged; Muramidase; Nystatin; Suppositories; Trichomonas Vaginitis

Topics: Candidiasis, Vulvovaginal; Female; Humans; Leukorrhea; Nystatin; Trichomonas Vaginitis

Topics: Candidiasis, Vulvovaginal; Female; Humans; Metronidazole; Nystatin; Trichomonas Vaginitis

Topics: Adult; Antiprotozoal Agents; Arsenicals; Borates; Carbohydrates; Ethinyl Estradiol; Female; Humans; Metronidazole; Nystatin; Penicillin Resistance; Penicillins; Progestins; Respiratory Tract Infections; Trichomonas Vaginitis

Topics: Adrenal Cortex Hormones; Amphotericin B; Anesthetics, Local; Candidiasis, Vulvovaginal; Female; Gentian Violet; Humans; Lactobacillus; Male; Metronidazole; Nystatin; Pruritus Ani; Pruritus Vulvae; Trichomonas Vaginitis; Vitamin B Complex

Topics: Adolescent; Candidiasis, Vulvovaginal; Child; Diabetes Mellitus; Drug Therapy; Female; Gonorrhea; Humans; Infant; Infant, Newborn; Metronidazole; Nystatin; Pregnancy; Trichomonas Vaginitis; Uterine Cervicitis; Vaginitis; Varicose Veins; Vulvar Neoplasms; Vulvitis; Vulvovaginitis

Topics: Adolescent; Adult; Anti-Bacterial Agents; Candidiasis, Oral; Candidiasis, Vulvovaginal; Female; Humans; Male; Metronidazole; Middle Aged; Nystatin; Trichomonas Vaginitis

Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Candidiasis, Vulvovaginal; Child; Female; Humans; Imidazoles; Metronidazole; Nystatin; Trichomonas Vaginitis; Vulvovaginitis

Topics: Adolescent; Candida; Candidiasis; Candidiasis, Vulvovaginal; Drug Therapy; Female; Fungicides, Industrial; Humans; Metronidazole; Nystatin; Preventive Medicine; Statistics as Topic; Trichomonas Infections; Trichomonas Vaginitis

Topics: Anthelmintics; Candidiasis, Vulvovaginal; Child; Female; Humans; Neisseria gonorrhoeae; Nystatin; Oxyuriasis; Penicillins; Streptococcal Infections; Streptomycin; Trichomonas Vaginitis; Virus Diseases; Vulvovaginitis